Fluoroquinolones
- 1 August 1989
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in International Journal of Clinical Pharmacy
- Vol. 11 (4), 124-127
- https://doi.org/10.1007/bf01987956
Abstract
The knowledge of side effects of fluoroquinolones during clinical trials and postmarketing surveillance is reviewed. Gastro-intestinal side effects (observed in 3–6% of the patients) are the most frequently observed side effects followed by side effects of the central nervous system (0.5–1.5%) and skin reactions (0.5–2%). The incidence of severe side effects is very low and most effects can be reserved rapidly upon discontinuation of therapy. Reactions of the central nervous system (sometimes severe) were the most often spontaneously reported events during the postmarketing surveillance of ofloxacin. The incidence of adverse reactions is usually in the same range as that of other antimicrobial agents like the third generation cephalosporins, imipenem and aztreonam. Fluoroquinolones are usually well-tolerated and safe drugs, but more data is needed on the long-term safety of quinolones, the safety in children, in elderly people and in severely ill patients.Keywords
This publication has 13 references indexed in Scilit:
- Spontaneous reporting of adverse drug reactions. I: the data.British Journal of Clinical Pharmacology, 1988
- [Severe reversible thrombopenia induced by norfloxacin].1987
- Norfloxacin and NeutropeniaAnnals of Internal Medicine, 1987
- Norfloxacin: Review of safety studiesAmerican Journal Of Medicine, 1987
- The adverse effects of fluoroquinolonesJournal of Antimicrobial Chemotherapy, 1987
- [Gyrase inhibitor: central nervous system side effects].1987
- [Gyrase inhibitors: unwanted central nervous system effects].1987
- Side Effects of Ofloxacin in Clinical Trials and in Postmarketing SurveillanceDrugs, 1987
- Crystalluria and Ciprofloxacin, Influence of Urinary pH and HydrationChemotherapy, 1986
- Norfloxacin disposition after sequentially increasing oral dosesAntimicrobial Agents and Chemotherapy, 1983